Placenta accreta spectrum (PAS) disorders are pathological attachment of the placenta to myometrium, where trophoblastic cells invade the uterine placental interface. PAS can lead to severe postpartum hemorrhage or even maternal death. Prenatal diagnosis of PAS is essential for optimal obstetric management to improve the pregnancy outcomes. However, in some low resource regions in China, less than 20% PAS are detected before delivery.

To explore the feasibility and universality of the bundled prevention and treatment strategy for placenta accreta spectrum disorders in different levels of medical institutions, and to investigate its effectiveness in improving the specialized disease management capabilities of medical institutions at all levels. We will conduct a regional, cluster-randomized trial to assess a multicomponent PAS management strategy to improve the prepartum detection rate of PAS.

Inclusion Criteria:

• Pregnant women who have regular prenatal examination at the research hospitals
• Pregnant women diagnosed with PAS before or after delivery

Exclusion Criteria:

• Pregnant women who have never been diagnosed with placental implantation disease throughout the pregnancy
• Pregnant women who were lost to follow-up during the study period

Pregnant women with placenta accreta spectrum disorders